iRadimed Quarterly Cash Flow Statement
NASDAQ: IRMDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
iRadimed free cash flow
In the quarter ended Jun 30, 2026, iRadimed generated $5.9 million of operating cash flow and spent $185,000 on capital expenditures. That left free cash flow of $5.8 million, a free-cash-flow margin of 28.1% of revenue. Free cash flow was up 12.6% from the prior year's $5.1 million.
iRadimed returned $2.6 million to shareholders through dividends, equal to 44% of free cash flow. Free cash flow covered dividend payments 2.3 times.
Summary generated from market data by MetaCap's automated system. Methodology
iRadimed cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 5.22M | 5.82M | 6.44M | 5.58M | 5.77M | 4.69M | 5.15M | 5.05M | 4.90M | 4.14M | 4.54M | 5.07M |
| Net Income growth (YoY) | -9.63% | +24.13% | +25.17% | +10.45% | +17.81% | +13.31% | +13.37% | -0.35% | +17.26% | +21.45% | +23.58% | +47.86% |
| Depreciation & Amortization | 410.00K | 455.00K | 380.68K | 383.32K | 208.00K | 194.00K | 195.21K | 197.57K | 199.13K | 226.09K | 205.38K | 189.90K |
| Stock-Based Compensation | 807.00K | 684.00K | 696.24K | 665.76K | 731.00K | 826.00K | 656.30K | 629.96K | 609.10K | 628.64K | 551.06K | 533.75K |
| Change in Working Capital | -208.00K | 358.00K | -174.31K | -2.88M | 1.15M | -1.02M | 1.21M | 2.64M | 1.63M | -1.58M | -1.32M | -4.14M |
| Operating Cash Flow | 5.94M | 8.29M | 5.92M | 6.99M | 7.75M | 4.29M | 5.99M | 9.12M | 6.64M | 3.88M | 3.91M | 1.39M |
| Capital Expenditures | -185.00K | -403.00K | -294.17K | -1.14M | -2.64M | -3.70M | -2.79M | -3.81M | -1.13M | -270.57K | -531.90K | -308.09K |
| Investing Cash Flow | -443.00K | -469.00K | -416.41K | -1.26M | -2.82M | -3.92M | -3.06M | -4.01M | -1.27M | -478.80K | -632.82K | -439.02K |
| Dividends Paid | -2.56M | -2.56M | -8.55M | -2.16M | -2.16M | -2.16M | -1.90M | -1.90M | -1.90M | -7.98M | 0 | 0 |
| Financing Cash Flow | -2.79M | -2.61M | -10.87M | -2.19M | -2.26M | -2.28M | -2.42M | -1.92M | -1.96M | -8.04M | -262.59K | -31.37K |
| Net Change in Cash | 2.71M | 5.21M | -5.37M | 3.53M | 2.67M | -1.90M | 513.15K | 3.19M | 3.41M | -4.64M | 3.02M | 922.29K |
| Free Cash Flow | 5.75M | 7.89M | 5.63M | 5.85M | 5.11M | 595.00K | 3.20M | 5.31M | 5.50M | 3.61M | 3.38M | 1.08M |
This table shows 12 quarterly periods of iRadimed's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IRMD's reporting calendar. What is a cash flow statement?